| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1803 | 2016 |
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 746 | 2018 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ... The lancet oncology 15 (6), 580-591, 2014 | 563 | 2014 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138, 2020 | 450 | 2020 |
| PI3K/Akt/mTOR inhibitors in breast cancer JJX Lee, K Loh, YS Yap Cancer biology & medicine 12 (4), 342, 2015 | 310 | 2015 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 296 | 2021 |
| Overall survival with ribociclib plus letrozole in advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, L Hart, ... New England Journal of Medicine 386 (10), 942-950, 2022 | 294 | 2022 |
| The NF1 gene revisited–from bench to bedside YS Yap, JR McPherson, CK Ong, SG Rozen, BT Teh, ASG Lee, DF Callen Oncotarget 5 (15), 5873, 2014 | 245* | 2014 |
| Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines IE Smith, M Dowsett, YS Yap, G Walsh, PE Lønning, RJ Santen, D Hayes Journal of Clinical Oncology 24 (16), 2444-2447, 2006 | 245 | 2006 |
| Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study YT Cheung, T Ng, M Shwe, HK Ho, KM Foo, MT Cham, JA Lee, G Fan, ... Annals of Oncology 26 (7), 1446-1451, 2015 | 225 | 2015 |
| Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells BL Khoo, ME Warkiani, DSW Tan, AAS Bhagat, D Irwin, DP Lau, AST Lim, ... PloS one 9 (7), e99409, 2014 | 217 | 2014 |
| Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ... The pharmacogenomics journal 15 (1), 84-94, 2015 | 209 | 2015 |
| An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells ME Warkiani, BL Khoo, DSW Tan, AAS Bhagat, WT Lim, YS Yap, SC Lee, ... Analyst 139 (13), 3245-3255, 2014 | 207 | 2014 |
| Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844–848 M Koczkowska, Y Chen, T Callens, A Gomes, A Sharp, S Johnson, ... The American Journal of Human Genetics 102 (1), 69-87, 2018 | 193 | 2018 |
| Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients JSL Lim, XA Chen, O Singh, YS Yap, RCH Ng, NS Wong, M Wong, ... British journal of clinical pharmacology 71 (5), 737-750, 2011 | 152 | 2011 |
| Chromosome 1q21. 3 amplification is a trackable biomarker and actionable target for breast cancer recurrence JY Goh, M Feng, W Wang, G Oguz, SMJM Yatim, PL Lee, Y Bao, TH Lim, ... Nature medicine 23 (11), 1319-1330, 2017 | 142 | 2017 |
| Neratinib+ capecitabine versus lapatinib+ capecitabine in patients with HER2+ metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Findings from the … C Saura, M Oliveira, YH Feng, MS Dai, SA Hurvitz, SB Kim, B Moy, ... Journal of Clinical Oncology 37 (15_suppl), 1002-1002, 2019 | 128 | 2019 |
| Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients YT Cheung, YL Foo, M Shwe, YP Tan, G Fan, WS Yong, P Madhukumar, ... Journal of clinical epidemiology 67 (7), 811-820, 2014 | 115 | 2014 |
| Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients YT Cheung, YL Foo, M Shwe, YP Tan, G Fan, WS Yong, P Madhukumar, ... Journal of clinical epidemiology 67 (7), 811-820, 2014 | 115 | 2014 |
